RxDoctor Payments Data

Samuel Hahn, MD

Otolaryngology/Facial Plastic Surgery · Baltimore, MDNPI 1982839635

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Abbott at 58.9% of the total. Reporting peaked in 2024 at $26,408 and has fallen 89.0% since, to $2,900 in 2025.

$41,079in general payments, 2019–2025

Across 143 payments — averaging $287.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$24K
  • AbbVie$14K
  • Revance Therapeutics, Inc.$770
  • Galderma Laboratories, L.p.$704
  • Aerin Medical Inc.$519
  • Regeneron Healthcare Solutions, Inc.$276
  • plus $531 from 11 others
$270in research payments, 2019–2025

Across 1 payment — averaging $270.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Aerin Medical Inc.$270

What the payments were for

  • Consulting fees$16,72541%
  • Speaking & faculty fees$13,92734%
  • Travel & lodging$8,07220%
  • Food & beverage$2,3556%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few otolaryngology/facial plastic surgery providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$163,765
Medicare patients
344
Services billed
2,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide45$675
Famotidine27$282
Fluticasone Propionate13$127
Mupirocin25$125
Cephalexin41$122
Montelukast Sodium14$110
Triamcinolone Acetonide15$107
Methylprednisolone16$73
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$68
Ondansetron OdtOndansetron12$52
Tramadol Hcl15$34
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$26

Paid to pharmacies, not to this prescriber.

Other otolaryngology/facial plastic surgery in Baltimore

Where these figures come from

Is this you, or does something look wrong? →